The Government of Castilla-La Mancha will acquire 150,000 doses of pneumococcal conjugate vaccine of 20 serotypes, intended for people over 65 or over 18 belonging to risk groups, with a planned investment of 6.8 million euros.
It is a new conjugate vaccine of 20 serotypes (VNC20) and developed by the Pfizer laboratory, which was approved by the European Commission in February 2022.
As regards Spain, following the decision on financing and fixing amounts of the Interministerial Commission on Medicine Prices, on August 1, 2022, the marketing of this vaccine was authorized throughout the national territory; while, in February 2023, the Vaccination Advisory Group of the General Directorate of Public Health of the Ministry of Health of Castilla-La Mancha finally approved the new recommendations for immunization with VNC20 .
Pneumococcal disease is one of the leading causes of vaccine-preventable death worldwide. /
